<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838873</url>
  </required_header>
  <id_info>
    <org_study_id>SO1901-31004</org_study_id>
    <nct_id>NCT04838873</nct_id>
  </id_info>
  <brief_title>Trial of Open Versus Laparoscopic Radical Cystectomy at a Laparoscopic Naive Center</brief_title>
  <official_title>Randomised Controlled Trial of Open Versus Laparoscopic Radical Cystectomy at a Laparoscopic Naive Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective randomised controlled study of urinary bladder cancer patients&#xD;
      presented to urology unit at National Cancer Institute; Cairo University.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will randomise 60 patients to one of two arms; laparoscopic-assisted radical&#xD;
      cystectomy and open radical cystectomy. The focus of the study will be a comparison of both&#xD;
      approaches on the patients' peri-operative outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative time</measure>
    <time_frame>During surgery</time_frame>
    <description>OR time as measured in minutes, divided into time required to perform the cystectomy, lymph node dissection, and urinary diversion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>During surgery</time_frame>
    <description>EBL as measured in millilitres, including the effluent from the suction canister as well as estimates of the gauze swabs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Immediate post-operative period.</time_frame>
    <description>LOS as measured in days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to oral intake</measure>
    <time_frame>Immediate post-operative period</time_frame>
    <description>Measured in days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conversion rate</measure>
    <time_frame>During surgery</time_frame>
    <description>Rate of conversion from laparoscopy to open surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Re-admission rate.</measure>
    <time_frame>Intra-operative to sixth months.</time_frame>
    <description>Re-hospitalization requirement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid requirements.</measure>
    <time_frame>During surgery through first post-operative week.</time_frame>
    <description>Requirement, dose and duration of narcotic analgesia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visceral injury</measure>
    <time_frame>During surgery</time_frame>
    <description>Any organ injury encountered during the operation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine leak</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Leakage of urine from urinary enteric anastomosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound dehiscence, infection.</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Wound gaping, evisceration or infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Enteric fistula</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Leakage of intestinal contents due to failure of entero-enteric anastomosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sepsis</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Infection triggering a systematic immune response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Venous thromboembolism</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>DVT or pulmonary embolism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pT stage</measure>
    <time_frame>Within 10 days post surgery.</time_frame>
    <description>Pathologic tumor stage (Stage 1, stage 2, stage 3 or stage 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node retrieval</measure>
    <time_frame>Within 10 days post surgery.</time_frame>
    <description>Number of lymph nodes retrieved by open versus laparoscopic approaches.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pN stage</measure>
    <time_frame>Within 10 days post surgery.</time_frame>
    <description>Lymph node metastasis (positive or negative), and number of positive nodes if present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical margins</measure>
    <time_frame>Within 10 days post surgery</time_frame>
    <description>Positive margins or negative margins. Location of positive margins (Urethral, ureteric)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological grade</measure>
    <time_frame>Within 10 days post surgery</time_frame>
    <description>Low grade, intermediate grade or high grade</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Laparoscopy</condition>
  <arm_group>
    <arm_group_label>Open Radical Cystectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard open radical cystectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic-assisted radical cystectomy.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic-assisted radical cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open radical cystectomy</intervention_name>
    <description>Standard open radical cystectomy and urinary diversion</description>
    <arm_group_label>Open Radical Cystectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic-assisted radical cystectomy</intervention_name>
    <description>Laparoscopic-assisted radical cystectomy and extracorporeal urinary diversion</description>
    <arm_group_label>Laparoscopic-assisted radical cystectomy.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with transitional cell carcinoma, squamous cell carcinoma and urinary bladder&#xD;
             adenocarcinoma.&#xD;
&#xD;
          -  Patients fit for surgery (ECOG Performance Status 0,1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with medical comorbidities that preclude surgical management or minimally&#xD;
             invasive techniques.&#xD;
&#xD;
          -  Patients with advanced hydronephrosis or renal failure.&#xD;
&#xD;
          -  Patients refusing surgery.&#xD;
&#xD;
          -  Patients with urinary bladder cancer invading bladder neck or prostatic urethra.&#xD;
&#xD;
          -  Patients with metastatic urinary bladder cancer.&#xD;
&#xD;
          -  Patients who received prior pelvic radiotherapy.&#xD;
&#xD;
          -  Patients refusing randomization and/or participation in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hatem Aboulkassem, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Abdelbary Ali</investigator_full_name>
    <investigator_title>Lecturer of Surgical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

